Food Reward in Native American Women

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by University of Minnesota - Clinical and Translational Science Institute
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01623440
First received: June 12, 2012
Last updated: November 5, 2013
Last verified: November 2013
  Purpose

This study aims to characterize the neurobiology of obesity in American Indians (AI) using functional MRIs to examine the correlation between brain response to food stimuli in AI women. A functional MRI (fMRI) is used to visualize brain activity when obese and lean AI women look at images of fattening food, non-fattening food and non-food objects. Additionally examined is the effect of the drug naltrexone to suppress brain response to visual food cues and calorie intake in the women.


Condition Intervention Phase
Obesity
Drug: Placebo
Drug: Naltrexone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Neural Correlates of Food Reward in Native American Women

Resource links provided by NLM:


Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • fMRI activation in the brain in response to visual food cue [ Time Frame: With In 30days ] [ Designated as safety issue: No ]
    fMRI activation in the brain in response to visual food cue


Estimated Enrollment: 60
Study Start Date: November 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Obese
BMI over 30
Drug: Placebo
Pill form, participant dosed one time an hour before fMRI.
Drug: Naltrexone
50 mg pill given one time, one hour before fMRI
Lean
BMI between 20 and 24.9
Drug: Placebo
Pill form, participant dosed one time an hour before fMRI.
Drug: Naltrexone
50 mg pill given one time, one hour before fMRI

Detailed Description:

The study looks at both obese and lean women. Each woman comes in for two visits. Each woman takes both the Naltrexone or placebo (one during each visit). Research staff and participants are blinded. Drugs are not used as treatment, but rather to provide information for possible future treatments.

Hypotheses are:

  1. Compared with their lean counterparts, obese women will demonstrate more fMRI activation in the brain in response to visual food cues.
  2. Naltrexone will reduce the activation in reward-relevant brain sites in response to viewing photographs of fattening food as compared in placebo in both groups.
  3. Naltrexone will suppress spontaneous intake of food in obese and lean AI women.
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female
  • Self-identified AI
  • BMI over 30 OR between 20 and 24.9
  • Must see clearly with or without glasses
  • Capable of giving informed consent

Exclusion Criteria:

  • Smokes more than one cigarette a day
  • Drinks more than two alcoholic drinks a day
  • Uses recreational drugs
  • Is pregnant
  • Has had weight loss surgery
  • Other major medical problems (e.g. diabetes)
  • Taking medications that alter appetite or body weight
  • Significant food allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01623440

Contacts
Contact: Lily Rubenstein, BA 612-624-8259 ruben048@umn.edu

Locations
United States, Minnesota
Fairview Clinic 1E Recruiting
Minneapolis, Minnesota, United States, 55455
Principal Investigator: Tiffany Beckman, MD, MPH         
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Investigators
Principal Investigator: Tiffany Beckman, MD, MPH Division of Endocrinology, Diabetes & Metabolism, University of Minnesota Department of Medicine
  More Information

No publications provided

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT01623440     History of Changes
Other Study ID Numbers: 10152
Study First Received: June 12, 2012
Last Updated: November 5, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Naltrexone
Narcotic Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014